Codon optimization of human factor VIII cDNAs leads to high-level expression
Open Access
- 20 January 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 117 (3) , 798-807
Abstract
Gene therapy for hemophilia A would be facilitated by development of smaller expression cassettes encoding factor VIII (FVIII), which demonstrate improved biosynthesis and/or enhanced biologic properties. B domain deleted (BDD) FVIII retains full procoagulant function and is expressed at higher levels than wild-type FVIII. However, a partial BDD FVIII, leaving an N-terminal 226 amino acid stretch (N6), increases in vitro secretion of FVIII tenfold compared with BDD-FVIII. In this study, we tested various BDD constructs in the context of either wild-type or codon-optimized cDNA sequences expressed under control of the strong, ubiquitous Spleen Focus Forming Virus promoter within a self-inactivating HIV-based lentiviral vector. Transduced 293T cells in vitro demonstrated detectable FVIII activity. Hemophilic mice treated with lentiviral vectors showed expression of FVIII activity and phenotypic correction sustained over 250 days. Importantly, codon-optimized constructs achieved an unprecedented 29- to 44-fold increase in expression, yielding more than 200% normal human FVIII levels. Addition of B domain sequences to BDD-FVIII did not significantly increase in vivo expression. These significant findings demonstrate that shorter FVIII constructs that can be more easily accommodated in viral vectors can result in increased therapeutic efficacy and may deliver effective gene therapy for hemophilia A.Keywords
This publication has 49 references indexed in Scilit:
- Functional roles of the factor VIII B domainHaemophilia, 2009
- Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vectorBlood, 2009
- Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia AMolecular Therapy, 2009
- Comparison of Factor VIII Transgenes Bioengineered for Improved Expression in Gene Therapy of Hemophilia AHuman Gene Therapy, 2009
- Antioxidants reduce endoplasmic reticulum stress and improve protein secretionProceedings of the National Academy of Sciences, 2008
- Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct MinimaJournal of Molecular Biology, 2008
- Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodiesJournal of Clinical Investigation, 2006
- Efficient expression of a transgene in platelets using simian immunodeficiency virus‐based vector harboring glycoprotein Ibα promoter: in vivo model for platelet‐targeting gene therapyThe FASEB Journal, 2006
- Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectorsBlood, 2003
- Factor VIII C2 Domain Missense Mutations Exhibit Defective Trafficking of Biologically Functional ProteinsJournal of Biological Chemistry, 1996